Cal Poly SLO receives DOE grant
Cal Poly San Luis Obispo received a $1.2 million grant from the Department of Education Sept. 1 to help economically disadvantaged students. The five-year grant will help support Cal Poly’s Educational Talent Search, which assists middle-school and high-school students who might not otherwise be able to afford college. About 500 students participate in Cal Poly’s Read More →
Read More →Amgen acquires German drug
Story updated at 11 a.m.: Thousand Oaks-based biotech giant Amgen acquired global development rights to a multiple myeloma drug from a German company Sept. 1. Amgen said in a news release it acquired commercial and development rights to BI 836909, which is currently being developed by German company Boehringer Ingelheim. It will work with Boehringer Read More →
Read More →Westlake Village Inn to host Rams radio show
The Westlake Village Inn announced Aug. 29 that ESPNLA 710AM will host a radio show with Los Angeles Rams head coach Jeff Fisher from the Bogies Bar and Lounge at the hotel in Westlake Village. The weekly show will air from 6 to 7 p.m. each week beginning Sept. 13 and running through the end Read More →
Read More →Jackson bill passes Senate
A bill authored by State Sen. Hannah-Beth Jackson, D-Santa Barbara, that could expand paternity leave for small business employees passed the Senate and now heads to the desk of Gov. Jerry Brown. Senate Bill 654 will expand the state’s Paid Family Leave Program to employees at small businesses with 20 to 49 employees. Current law Read More →
Read More →Semtech Q2 revenues soar
Semtech revenues increased along with profits and earnings per share during the second quarter of fiscal year 2017 the company announced Aug. 31. Semtech, a Camarillo-based manufacturer of semi-conductors for the smartphone industry, released quarterly earnings results Aug. 31. Revenues increased 8 percent from $125.7 million during the same quarter last year to $135.9 million Read More →
Read More →FDA approves biosimilar of Amgen’s Enbrel
The U.S. Food and Drug Administration formally approved a competing biosimilar of Amgen’s top-selling drug Enbrel on Aug. 30. Made by Switzerland-based Novartis, Erelzi mimics the effects of Enbrel. Enbrel, which was first approved in 1998, is approved to treat rheumatoid arthritis and other conditions by decreasing the amount of a protein produced by the Read More →
Read More →Amgen reports positive results for Prolia
Thousand Oaks-based biotech giant Amgen announced positive results from patients receiving Prolia to treat inflammation Aug. 29. In the study, Prolia, normally used to treat osteoporosis, hypercalcemia and bone cancer, was used to treat inflammation. The two-year study enrolled 795 patients to evaluate the safety of two 60 milligram doses of Prolia given under the Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
